Benzene and Acute Myeloid Leukemia: Examining the Causal Link

From General Health Awareness to Occupational Risk

The legacy heritage of general health and science information has long provided foundational knowledge on environmental factors and their potential links to disease. Within this broad context, public databases and educational resources have historically emphasized the importance of understanding chemical exposures in everyday life. Benzene, a widely recognized industrial solvent, has been a subject of such general health discussions, often framed around its presence in air pollution, gasoline, and consumer products. This background has established a baseline awareness of benzene as a substance warranting caution, yet the focus has remained on population-level risks and regulatory guidelines rather than specific occupational scenarios. Transitioning from this general health perspective, the concern narrows significantly when considering occupational exposure. In mass production environments, particularly those involving chemical manufacturing, petroleum refining, or rubber production, workers may encounter benzene at higher concentrations and with greater frequency than the general public. This shift in context moves the discussion from ambient, low-level exposure to a more concentrated, workplace-specific risk profile.

Benzene as a Myelotoxin and Human Carcinogen

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene has been linked to an increased risk of developing acute myeloid leukemia (AML), a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, along with potential extramedullary involvement. Diagnosis is confirmed through peripheral blood smear, bone marrow aspiration, and biopsy, with cytogenetic and molecular testing used to classify subtypes and guide treatment. The pharmacological profile of benzene includes its metabolism primarily in the liver via cytochrome P450 enzymes, producing reactive metabolites such as benzene oxide, phenol, hydroquinone, and 1,4-benzoquinone. These metabolites can circulate to the bone marrow, where they exert toxic effects. Reported adverse effects of benzene exposure include hematotoxicity, immunosuppression, and genotoxicity. The carcinogenic ability of benzene has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Mechanistic Pathways Linking Benzene to AML

Mechanistic pathways linking benzene to AML involve multiple key events. Possible mechanisms of benzene initiation of hematological tumors have been identified, as a genotoxic effect, an action on oxidative stress and inflammation and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and the other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action (MOA) for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by the myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Epidemiological Evidence and Risk Anchors

Regarding risk anchors, the adequacy of warnings about benzene and AML is a critical consideration. Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of acute myeloid leukaemia (AML) (https://pubmed.ncbi.nlm.nih.gov/33429013/). Previous studies established a causal relationship between occupational benzene exposure and acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/38727681/). In a national cohort from Switzerland, we found that occupational exposure to benzene is associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). These findings underscore the importance of adequate warnings and exposure controls in occupational settings. Causation-related considerations for affected patients include the need to document exposure history, latency periods, and potential confounding factors. The timeline between exposure and documented harm can vary. Of 1,632 studies screened after duplicate removal, 25 met the inclusion criteria. The findings indicated an elevated risk of acute lymphoblastic leukemia (ALL) in children exposed to PM2.5 (OR: 1.29, 95% CI: 1.01-1.63; 5 studies; I2 = 72.1%), and increased risks of all childhood cancers (OR: 1.12, 95% CI: 1.02-1.22; 4 studies; I2 = 0.0%) and acute myeloid leukemia (AML, OR: 1.22, 95% CI: 1.02-1.46; 4 studies; I2 = 0.0%) associated with benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). This meta-analytic evidence supports a statistically significant association between benzene exposure and AML risk, with a 22% increased odds per unit increase in exposure. In summary, the evidence consistently demonstrates that benzene causes acute myeloid leukemia through genotoxic, oxidative stress, and immunosuppressive mechanisms. Adequate warnings and exposure monitoring are essential to mitigate risk, and affected patients should be evaluated with consideration of exposure history and latency.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does benzene cause acute myeloid leukemia?

Yes, benzene is a recognized human carcinogen and myelotoxin. Chronic exposure to benzene has been consistently linked to an increased risk of developing acute myeloid leukemia (AML) through genotoxic, oxidative stress, and immunosuppressive mechanisms. Epidemiological studies have established a causal relationship, particularly in occupational settings with exposure levels of 10 ppm or more (https://pubmed.ncbi.nlm.nih.gov/34069279/, https://pubmed.ncbi.nlm.nih.gov/33429013/, https://pubmed.ncbi.nlm.nih.gov/38727681/).

What are the mechanisms by which benzene causes AML?

Benzene is metabolized in the liver to reactive metabolites such as benzene oxide, phenol, hydroquinone, and 1,4-benzoquinone, which circulate to the bone marrow. These metabolites cause genotoxicity, oxidative stress, inflammation, and immunosuppression, leading to hematotoxicity and genetic damage in blood cells. These early key events can progress to myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/34069279/, https://pubmed.ncbi.nlm.nih.gov/33429013/).

What level of benzene exposure is associated with increased AML risk?

Occupational exposure to benzene at levels of 10 ppm or more has been associated with an increased risk of acute myeloid leukemia. Studies have shown a dose-response relationship, with higher cumulative exposure leading to greater risk (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.